liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Hormonal Therapy, Progression to Castration-resistant Prostate Cancer and Survival
Linköping University, Department of Biomedical and Clinical Sciences, Division of Surgery, Orthopedics and Oncology. Linköping University, Faculty of Medicine and Health Sciences.
2025 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Background: Prostate cancer (Pca) is the most common cancer among men in Sweden and a leading cause of cancer-related death in the world. Hormonal therapy is a cornerstone for management of high-risk and advanced disease, but there are some uncertainties regarding some treatment combinations, predictors of disease progression, and the application of guideline-based definitions for castration-resistant prostate cancer (CRPC).

Materials and Methods: This thesis includes four population-based studies and uses data from Swedish national registers and patient records. Study I compared Pca mortality in men treated with radiotherapy combined with bicalutamide, GnRH analogues, or both. Study II examined whether PSA levels after androgen deprivation therapy (ADT), combined with ISUP grade, predict progression to CRPC and Pca death. Study III evaluated how guideline-based CRPC definitions are applied in clinical practice. Study IV assessed whether 5α-reductase inhibitors (5ARIs) introduce histological grading bias.

Results: In Study I, there was no significant difference in Pca mortality between adjuvant bicalutamide and GnRH analogues following neoadjuvant combined androgen blockade (CAB). However, bicalutamide monotherapy was associated with a two- to fourfold increased mortality compared to regimens including GnRH analogues in men treated with conventionally fractionated or brachytherapy-boosted radiotherapy. Study II showed that men with the highest combination of PSA after 3–6 months of ADT and ISUP grade had a fourfold higher risk of CRPC, with a median time to progression of 1.5 years compared to 7.8 years in the lowest-risk group. Study III showed that guideline-based CRPC definitions were not applied systematically, and many patients received CRPC-specific treatment without fulfilling criteria from guidelines. Moreover, that radiological progression was the most common event preceding treatment. In Study IV, we found no increased Pca mortality among 5ARI users within each Gleason grade group, arguing against a grading artifact.

Conclusion: Our findings show that the choice of hormonal therapy influences Pca mortality among men receiving radiotherapy, with bicalutamide monotherapy associated with worse outcomes than regimens including GnRH analogues (Study I). Early PSA response after initiation of ADT, combined with ISUP grade, was strongly predictive of CRPC progression and death allowing for the development of a simple risk stratification model (Study II). In clinical practice, guideline-based definitions of CRPC were inconsistently applied, and treatment decisions were often triggered by radiological progression (Study III). Finally, no increased risk of Pca death was observed among 5ARI users, suggesting that these agents do not introduce grading bias (Study IV).

Place, publisher, year, edition, pages
Linköping: Linköping University Electronic Press, 2025. , p. 64
Series
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1978
Keywords [en]
Prostate neoplasm, Hormonal therapy, Androgen deprivation therapy, Castration-resistant prostate cancer, Radiotherapy
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-217079DOI: 10.3384/9789181180824ISBN: 9789181180817 (print)ISBN: 9789181180824 (electronic)OAI: oai:DiVA.org:liu-217079DiVA, id: diva2:1993245
Public defence
2025-09-26, Aulan, Länssjukhuset Ryhov, Sjukhusgatan, Jönköping, Jönköping, 13:00 (Swedish)
Opponent
Supervisors
Available from: 2025-08-29 Created: 2025-08-29 Last updated: 2025-09-02Bibliographically approved
List of papers
1. Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
Open this publication in new window or tab >>Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
Show others...
2023 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 62, no 12Article in journal (Refereed) Published
Abstract [en]

Background

Oncological outcome after radical radiotherapy (RRT) combined with neoadjuvant and adjuvant androgen suppression therapy (AST) may differ according to type of AST. The aim of this nationwide register-based study was to investigate risk of prostate cancer (Pca) death after different neoadjuvant and adjuvant ASTs; (i) bicalutamide, (ii) gonadotropin-releasing hormone agonists (GnRH) or (iii) combined bicalutamide and GnRH (CAB), together with RRT.

Materials and Methods

Data for 6882 men diagnosed with high-risk Pca between 2007 and 2020 and treated with primary RRT was retrieved from Prostate Cancer data Base Sweden (PCBaSe) 5.0. Time to Pca death according to type of neoadjuvant and adjuvant AST was assessed by use of Kaplan–Meier plots and Cox proportional hazard models adjusted for putative confounders.

Results

Data were stratified by RRT type since the effect of AST in risk of Pca death differed according to type of RRT. Compared with the reference RRT combined with neoadjuvant CAB/adjuvant GnRH, risk of Pca death for men treated with CAB/bicalutamide and conventionally fractionated external beam radiotherapy (CF-EBRT) was hazard ratio (HR) 0.73 (95% CI: 0.50–1.04), hypofractionated EBRT (HF-EBRT), HR 1.35 (95% CI: 0.65–2.81) and EBRT with high dose rate brachytherapy (EBRT-HDRBT), HR 0.85 (95% CI: 0.37–1.95). Risk of Pca death for men treated with bicalutamide/bicalutamide and: (i) CF-EBRT was HR 2.35 (95% CI: 1.42–3.90), (ii) HF-EBRT, HR 0.70 (95% CI: 0.26–1.85), (iii) HF-EBRT, HR 4.07 (95% CI: 1.88–8.77) vs the reference.

Conclusion

In this observational study, risk of Pca death between men receiving different combinations of AST varied according to RRT type. No difference was found in risk of Pca death for men treated with bicalutamide or GnRH as adjuvant therapy to RRT following neoadjuvant CAB. Risk of Pca death was increased for men with monotherapy neo-/adjuvant bicalutamide in combination with CF-EBRT or EBRT-HDRBT.

Place, publisher, year, edition, pages
MJS Publishing, Medical Journals Sweden AB, 2023
Keywords
Prostate neoplasms, androgen antagonists, gonadotropin-releasing hormone, radiotherapy, prognosis, mortality
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-217073 (URN)10.1080/0284186X.2023.2269600 (DOI)001085897400001 ()37850633 (PubMedID)2-s2.0-85174261493 (Scopus ID)
Conference
2025/08/28
Note

Funding: This project received research support from the Clinical Cancer Research Foundation in Jönköping, Sweden and from FUTURUM - Academy for Healthcare, JönköpingCounty, Sweden.

Available from: 2025-08-29 Created: 2025-08-29 Last updated: 2026-06-04Bibliographically approved
2. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists
Open this publication in new window or tab >>Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists
Show others...
2022 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 56, no 3, p. 169-175Article in journal (Refereed) Published
Abstract [en]

Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death by use of clinical variables at Pca diagnosis and PSA levels after start of gonadotropin-releasing hormone agonists (GnRH) in men with non-metastatic castration sensitive prostate cancer (nmCSPC).

Materials and Methods: PSA values for 1603 men with nmCSPC in the National Prostate Cancer Register of Sweden who received GnRH as primary treatment were retrieved from Uppsala-Örebro PSA Cohort and Stockholm PSA and Biopsy Register. All men had measured PSA before (pre-GnRH PSA) and 3–6 months after (post-GnRH PSA) date of start of GnRH. Unadjusted and adjusted Cox models were used to predict CRPC by PSA levels. PSA levels and ISUP grade were used to construct a risk score to stratify men by tertiles according to risk of CRPC and Pca death.

Results: 788 (49%) men reached CRPC and 456 (28%) died of Pca during follow-up. Post-GnRH PSA predicted CRPC regardless of pre-GnRH PSA. CRPC risk increased with higher post-GnRH PSA, HR 4.7 (95% CI: 3.4–6.7) for PSA > 16 ng/mL vs 0–0.25 ng/mL and with ISUP grade, HR 3.7 (95%: 2.5–5.4) for ISUP 5 vs ISUP 1. Risk of Pca death in men above top vs bellow bottom tertile of post-GnRH PSA and ISUP grade was HR 4.1 (95% CI: 3.0–5.5).

Conclusion: A risk score based on post-GnRH PSA and ISUP grade could be used for early identification of a target group for future clinical trials on additional therapy to GnRH.

Place, publisher, year, edition, pages
Taylor & Francis, 2022
Keywords
Prostatic neoplasms; prostatic neoplasms; castration-resistant; neo-plasm grading; prostate-specific antigen; gonadotropin-releasing hormone; prognosis; mortality
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-217075 (URN)10.1080/21681805.2022.2070275 (DOI)000794215300001 ()35548951 (PubMedID)2-s2.0-85130235285 (Scopus ID)
Note

Funding: This project received research support from the Swedish Cancer Society, the Swedish Research Council, the Clinical Cancer Research Foundation in Jönköping, Sweden [FUTURUM-964541] and from FUTURUM - Academy for Healthcare, Jönköping County, Sweden.

Available from: 2025-08-29 Created: 2025-08-29 Last updated: 2025-08-29Bibliographically approved
3. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death
Open this publication in new window or tab >>5α-Reductase Inhibitors and Risk of Prostate Cancer Death
2020 (English)In: Journal of Urology, ISSN 0022-5347, E-ISSN 1527-3792, Vol. 204, no 4, p. 714-719Article in journal (Refereed) Published
Abstract [en]

Purpose:

5α-Reductase inhibitors reduced the risk of prostate cancer in 25% in 2 randomized trials but increased the risk of Gleason 8-10 at biopsy. One explanation is that 5α-reductase inhibitors induce morphological changes in prostate cancer cells similar to higher Gleason grades but without its adverse biology. We compared risk of prostate cancer death between men on 5α-reductase inhibitors and men not on 5α-reductase inhibitors before prostate cancer diagnosis in each Gleason Grade Group.

Materials and Methods:

Prostate Cancer data Base Sweden consists of linkages between the National Prostate Cancer Register, the Prescribed Drug Registry and the Cause of Death Registry. Of 89,227 men diagnosed with prostate cancer between July 2007 and December 2016, 5,816 had been on 5α-reductase inhibitors for more than 180 days before the date of diagnosis. Followup ended in December 2018. A Cox proportional hazard model was used to assess hazard ratio for prostate cancer death. Adjustments for age, comorbidity, education and curative treatment were made. Men with high risk cancer were stratified according to Gleason Grade Group.

Results:

In men with high risk cancer the risk of prostate cancer death was similar among 5α-reductase inhibitor users and nonusers, with Gleason Grade Group 1 HR 1.02 (95% CI 0.53–1.95), Gleason Grade Group 2 HR 1.04 (95% CI 0.65–1.69), Gleason Grade Group 3 HR 1.27 (95% CI 0.89–1.80), Gleason Grade Group 4 HR 0.95 (95% CI 0.76–1.18) and Gleason Grade Group 5 HR 0.99 (95% CI 0.83–1.19), for 5α-reductase inhibitor users vs nonusers.

Conclusions:

We found no evidence that 5α-reductase inhibitors affect Gleason grading as no difference in mortality was observed among 5α-reductase inhibitor users and nonusers in each Gleason group.

Keywords
5-alpha reductase inhibitors, finasteride, dutasteride, prostatichyperplasia, neoplasm grading
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-217076 (URN)10.1097/ju.0000000000001038 (DOI)32243243 (PubMedID)
Available from: 2025-08-29 Created: 2025-08-29 Last updated: 2025-08-29Bibliographically approved

Open Access in DiVA

fulltext(5146 kB)592 downloads
File information
File name FULLTEXT01.pdfFile size 5146 kBChecksum SHA-512
f96553055d5fde465ef066620dfa4c0354d412b173b51d73420d6fd946410dd48ddb594c0851f95379fdb3bd948c84c63526a519ac24ae178b2aa294253dbb62
Type fulltextMimetype application/pdf
Order online >>

Other links

Publisher's full text

Authority records

Bonde Miranda, Tiago

Search in DiVA

By author/editor
Bonde Miranda, Tiago
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health Sciences
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 599 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
isbn
urn-nbn

Altmetric score

doi
isbn
urn-nbn
Total: 727 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf